A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma

Trial Profile

A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 28 Jun 2018

At a glance

  • Drugs Ipilimumab (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions
  • Acronyms IMAGE
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 10 Apr 2018 Planned End Date changed from 30 Mar 2020 to 28 Nov 2020.
    • 10 Apr 2018 Planned primary completion date changed from 29 Mar 2018 to 11 May 2020.
    • 10 Apr 2018 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top